Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5 VLP vaccine
- Development stage
- Discontinued
- Lead developer
- Medicago
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intradermal, Microneedle/skin Delivery
01
Overview
The H5 VLP vaccine is a plant-derived virus-like particle (VLP) influenza A (H5N1) pandemic and avian influenza candidate. It is produced by expressing the hemagglutinin (HA) gene from the target strain in *Nicotiana benthamiana* plants using transient expression technology. The resulting non-infectious particles mimic the structure of native viruses but lack viral genetic material. This design aims to stimulate robust immune responses without risk of infection. The primary mechanism is immunostimulation via presentation of HA antigens to elicit neutralizing antibodies and cellular immunity against diverse clades of highly pathogenic avian influenza (HPAI) H5 viruses[3][6][4]. Developed primarily by Medicago and tested with adjuvants such as alum for enhanced immunogenicity[6], it has been evaluated in both preclinical animal models and early-phase human clinical trials for safety and efficacy.
- Other names
- Plant-made H5 VLP influenza vaccinePlant-based H5 virus-like particle (VLP) vaccineOne-dose H5N1 VLP vaccinePandemic flu vaccine - Medicago
02
Targets
N1 NA (Influenza A neuraminidase N1)HA (Hemagglutinin)
Beyond the preview
Go deeper on H5 VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5 VLP vaccine.